Recobent 2k Injection contains Recombinant Human Erythropoietin Alfa 2000 IU, a biosynthetic erythropoiesis-stimulating agent used for the treatment of anemia related to chronic kidney disease, chemotherapy, and other conditions causing reduced red blood cell production.
Recombinant Human Erythropoietin Alfa stimulates bone marrow to increase red blood cell formation, improving hemoglobin levels and reducing dependence on blood transfusions. This controlled mechanism supports long-term anemia management.
The lower-strength injectable option allows flexible dosing, especially in early therapy or maintenance phases. Its predictable clinical response and hospital acceptance make it a reliable product across nephrology, oncology, and critical care settings.
Adding Recobent 2k Injection to your injectable and anemia care portfolio enhances your offerings with an essential, high-utility molecule. Its institutional demand, prescriber trust, and export potential make it well-suited for PCD pharma companies, distributors, and third-party manufacturing partnerships.